SHANGHAI, Dec. 5, 2022
/PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or
the "Company"), a platform-based internet technology company
offering services to patients with oncology and other major
diseases, today announced that after three years of preparation,
the Company's MDMOOC platform has established a
"Surgical-Interventional-Drug" ("SID") platform for liver cancer
comprehensive-disciplinary physician education ("SID Platform"),
providing physicians with knowledge and techniques in
comprehensive-disciplinary comprehensive management of patients
with liver cancer.
According to The Global Cancer Observatory, there were around
400,000 new liver cancer cases in 2020 in China. In the context of the increasing number
of liver cancer patients in China,
the National Health Commission of the
People's Republic of China has promulgated authoritative
liver cancer diagnosis and treatment guiding documents, such as the
"Standardization of Diagnosis and Treatment for Hepatocellular
Carcinoma," "Expert Consensus on Conversion Therapy for
Hepatocellular Carcinoma" and "Expert Guidance on the Comprehensive
Management of Liver Cancer Patients during the Covid-19 Pandemic"
to guide the clinical treatment of liver cancer. In recent years,
significant progress has been made in the surgical, interventional,
pharmacological and radiological treatment of liver cancer in
China.
The SID Platform created by Zhongchao targets physicians from
different levels and covers comprehensive disciplines of liver
cancer treatment: hepatobiliary surgery, interventional and medical
oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer
disciplines, the SID Platform designs and provides clinical
diagnosis and treatment education courses in liver cancer and
provides a technical platform for clinicians to share experiences
and discuss clinical challenges. As of today, the courses on the
SID Platform were taken approximately 290,000 times by liver cancer
physicians. Zhongchao believes that its SID Platform provides a
platform for liver cancer physicians, especially for junior and
intermediate physicians to present themselves, learn knowledge and
techniques, and communicate with peers, which promotes new liver
cancer treatment concepts such as conversion therapy, comprehensive
patient management and standardized interventional treatments.
Zhongchao expects its SID Platform to serve as a new model of
promotion and education platform, contribute to the lifelong
learning and professional development of liver cancer physicians,
and eventually benefit liver cancer patients.
About Zhongchao Inc.
Zhongchao Inc. is an offshore holding company incorporated in
the Cayman Islands. It conducts
operations in China through the
contractual arrangements between its wholly owned subsidiary and
PRC operating entities. Zhongchao Inc. is a platform-based internet
technology company offering services to patients with oncology and
other major diseases. The PRC operating entities provide online
healthcare information, professional training and educational
services to healthcare professionals under their "MDMOOC" platform
(www.mdmooc.org), offer patient management services in the
professional field of tumor and rare diseases through Zhongxin,
offer internet healthcare services through Zhixun Internet
Hospital, and pharmaceutical services through Xinjiang Medical and
operate an online information platform, Sunshine Health Forums, to
general public. More information about the Company can be found at
its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; the growth
of the professional training and educational services market in
China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions in
China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and severity
of the recent coronavirus outbreak, including its impacts across
our business and operations. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-established-sid-liver-cancer-comprehensive-disciplinary-physician-education-platform-301691837.html
SOURCE Zhongchao Inc.
